Author

R. Tirtakusuma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

D. Pal· 2 shared H. McNeill· 2 shared S. Nakjang· 2 shared A. Elder· 1 shared A. Filby· 1 shared A. Fuller· 1 shared A. Isa· 1 shared A. Komkov· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Pal

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic regulator genes direct lineage switching in MLL-AF4 leukaemia

R. Tirtakusuma, K. Szoltysek, P. Milne, V. V. Grinev, A. Ptasinska, C. Meyer, S. Nakjang, J. Y. Hehir-Kwa, D. Williamson, P. Cauchy, S. A. Assi, M. R. Imperato, F. Vogiatzi, S. Lin, M. Wunderlich, , M. J Thirman

This study shows that lineage switching in MLL-AF4 leukaemia is driven by dysregulation of epigenetic regulators like NuRD, leading to reprogramming of gene regulatory networks from B lymphoid to myeloid.

bioRxiv · Jul 16, 2021Cancer Biology

An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia

D. Pal, H. Blair, S. Boyd, S. Angel, S. Nizami, A. Isa, M. Beckett, R. Nelson, A. Wilson, M. Singh, S. Sankar, R. Tirtakusuma, S. Nakjang, C. Knill, A. Fuller, , J. Vormoor

This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.

bioRxiv · Jun 18, 2021Cancer Biology